TAT and ischemia: In the Tat-PDIA3-treated group, SOD2 activity significantly increased (1.249- and 1.271-fold, respectively) compared with the vehicle-treated group 24 h and 72 h after ischemia/reperfusion, and to the control (Figure 5f).